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Abstract
Ovarian cancer is the leading cause of death from gynecologic malignancies yet the 
underlying pathophysiology is not clearly established. Epithelial ovarian cancer (EOC) 
has long been considered a heterogeneous disease with respect to histopathology, molec-
ular biology, and clinical outcome. Treatment of ovarian cancer includes a combination 
of cytoreductive surgery and combination chemotherapy, with platinums and taxanes. 
Despite initial success, over 75% of patients with advanced disease will relapse around 
18 months and the overall 5-year survival is approximately 50%. Cancer cells are known 
to be under intrinsic oxidative stress, which alters their metabolic activity and reduces 
apoptosis. Epithelial ovarian cancer has been shown to manifest a persistent pro-oxidant 
state as evident by the upregulation of several key oxidant enzymes in EOC tissues and 
cells. In the light of our scientific research and the most recent experimental and clinical 
observations, this chapter provides the reader with up to date most relevant findings on 
the role of oxidative stress in the pathogenesis and prognosis of ovarian cancer, as well as 
a novel mechanism of apoptosis/survival in EOC cells.
Keywords: ovarian cancer, oxidative stress, chemoresistance, apoptosis, nitrosylation, 
caspase-3
1. Introduction
Ovarian cancer is the fifth leading cause of cancer death; the leading cause of death from gyne-
cologic malignancies, and the second most commonly diagnosed gynecologic malignancy; yet 
the underlying pathophysiology continues to be delineated [1, 2]. Epithelial ovarian cancer 
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has long been considered a heterogeneous disease with respect to histopathology, molecular 
biology, and clinical outcome. It comprises at least five distinct histological subtypes, the most 
common and well-studied being high-grade serous ovarian cancer (HGSOC) [3]. The majority 
of advanced-stage tumors are of epithelial cell origin and can arise from serous, mucinous, or 
endometrioid cells on the surface epithelium of the ovary or the fallopian tube [2]. The most 
obvious clinical implication of tumor heterogeneity is that molecular-targeted therapy, while 
being effective at one tumor site, may not be as effective at all of them [3].
Because early-stage ovarian cancer presents with nonspecific symptoms, most often diagnosis is 
not made until after the malignancy has spread beyond the ovaries [4]. Mortality rates for this 
type of malignancy are high because of a lack of a sensitive and specific early-stage screening 
method [4]. Surgical cytoreduction followed by platinum/taxane chemotherapy results in com-
plete clinical response in 50–80% of patients with stage III and IV disease, but most will relapse 
within 18 months and ultimately develop chemoresistant disease [2]. Resistance to chemotherapy 
can either be intrinsic, occurring at the onset of treatment, or acquired, when the disease recurs 
despite an initially successful response [5–7]. Attempts to overcome drug resistance are central to 
both clinical and basic molecular research in cancer chemotherapy [5, 8]. Cancer cells are known 
to be under intrinsic oxidative stress, resulting in increased DNA mutations or damage, genome 
instability, and cellular proliferation [9–13]. The persistent generation of cellular reactive oxygen 
species (ROS) is a consequence of many factors including exposure to carcinogens, infection, 
inflammation, environmental toxicants, nutrients, and mitochondrial respiration [14–17].
The origin and causes of ovarian tumors remains under debate. Injury to surface epithelial 
ovarian cells due to repeated ovulation is thought to induce tumorigenesis in these cells and 
is known as the “incessant ovulation hypothesis.” Additionally, hormonal stimulation of the 
surface epithelium of the ovary has been described to initiate tumorigenesis in surface epithe-
lial cells and is known as the “gonadotropin hypothesis.” Moreover, the fallopian tube, and 
not the ovary, has been suggested to be the origin for most epithelial ovarian cancer [2, 18, 19]. 
Nevertheless, many cases of ovarian cancer continue to be described as de novo.
Histopathologic, clinical and molecular genetic profiles were successfully utilized to clearly 
discriminate between type I and type II ovarian tumors [19]. Accordingly, type I ovarian 
tumors develop from benign precursor lesions that implant on the ovary and include clear 
cell, endometrioid, low-grade serous carcinomas, mucinous carcinomas and malignant 
Brenner tumors [19]. Type II ovarian tumors develop from intraepithelial carcinomas of the 
fallopian tube and can then spread to involve both the ovary as well as other sites, such as 
high-grade serous carcinomas which comprise morphologic and molecular subtypes [19]. 
Additionally, high-grade endometrioid, poorly differentiated ovarian cancers, and carcino-
sarcomas are also classified as type II tumors.
Attempts to identify specific genes in ovarian tumors to help in early detection of the disease and 
serve as targets for improved therapy had failed to identify reproducible prognostic indicators 
[2, 20–22]. Several oncogenic mutations and pathways have been identified in ovarian cancer. 
Specific inherited mutations in the BRCA1 and BRCA2 genes that produce tumor suppressor 
proteins, are known to be associated with a 15% increased risk of ovarian cancer overall [2]. 
Ovarian cancers associated with BRCA1 and BRCA2 mutations are much more common in 
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younger age patients as compared with their nonhereditary counterparts. Additionally, somatic 
gene mutations in RAD51C and D, HNPCC, NF1, RB1, CDK12, P53, BRAF, KRAS, PIK3CA, 
and PTEN have been identified in epithelial ovarian cancer. Somatic mutations in BRAF and 
KRAS genes are relatively common in type I tumors, while p53 mutations, RAS signaling and 
PIK3CA are common in type II. Additional genetic variations have been hypothesized to act as 
low to moderate alleles, which contribute to ovarian cancer risk, as well as other diseases [23].
Ovarian tumors are distinct from many other type of cancers as they rarely metastasize out-
side of the peritoneal cavity [24]. Ovarian tumors are spread into the peritoneal cavity when 
cells from the primary tumor detach and travel into the peritoneum where they implant into 
the mesothelial lining [25]. Metastases beyond the peritoneum are usually restricted to recur-
rent or advanced disease; however, pleural metastases were reported to be present at initial 
diagnosis. Moreover, the recent discovery of ovarian cancer stem cells, which manifest prop-
erties of typical cancer stem cells, in ascites is a new additional contributing factor to not only 
to metastasis but also to chemoresistance [25, 26].
2. Oxidative stress
Homeostasis, the balance between the production and elimination of oxidants, is maintained 
by mechanisms involving oxidants and antioxidant enzymes and molecules. If this balance is 
altered, it leads to an enhanced state of oxidative stress that alters key biomolecules and cells 
of living organism [13]. Oxidant molecules are divided into two main groups; oxygen-derived 
or nitrogen-containing molecules. Oxygen-derived molecules, also known as reactive oxygen 
species (ROS), includes free radicals such as hydroxyl (HO●), superoxide (O
2
●−), peroxyl (RO
2
●), 
and alkoxyl (RO●), as well as oxidizing agents such as hydrogen peroxide (H
2
O
2
), hypochlorous 
acid (HOCl), ozone (O
3
), and singlet oxygen (1O
2
) that can be converted to radicals [13, 27]. 
Nitrogen containing oxidants, also known as reactive nitrogen species (RNS), are derived from 
nitric oxide (NO) that is produced in the mitochondria in response to hypoxia [13]. Exposure 
to inflammation, infection, carcinogens, and toxicants are major sources of ROS and RNS, in 
vivo [13, 16, 27, 28]. Additionally, RNS and ROS can be produced by various enzymes including 
cytochrome P450, lipoxygenase, cyclooxygenase, nicotinamide adenine dinucleotide phosphate 
(NAD(P)H) oxidase complex, xanthine oxidase (XO), and peroxisomes (Figure 1) [13, 28, 29].
To maintain the redox balance, ROS and RNS are neutralized by various important enzyme 
systems including superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase 
(GST), glutathione (GSH), thioredoxin coupled with thioredoxin reductase, glutaredoxin, glu-
tathione peroxidase (GPX), and glutathione reductase (GSR) (Figure 1) [27]. Superoxide dis-
mutase is known to convert O
2
●– to H
2
O
2
, which is then converted to water by CAT. Glutathione 
S-transferase is involved in detoxification of carcinogens and xenobiotics by catalyzing their 
conjugation to GSH that will aid in expulsion from the cell (Figure 1) [27]. Indeed, the GSH-
to-oxidized-GSH (GSH/GSSG) ratio is a good indicator of cellular redox buffering capacity 
[30, 31]. Under enhanced oxidative stress, the GSH/GSSG complex is known to stimulate the 
activity of the GS-X-MRP1 efflux pump, which removes toxins from cells. This mechanism 
has been investigated in the development of resistance to chemotherapeutic drugs [30, 31].
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3. Oxidative stress and cancer
Oxidative stress has been implicated in the etiology of several diseases, including cancer. 
Alteration of the cellular redox balance modulates the initiation, promotion, and progression 
of tumor cells [13, 27]. The continuous generation of oxidants and free radicals affects key 
cellular mechanisms that control the balance of cell proliferation and apoptosis, which play 
a major role in the initiation and development of several cancers. Depending on the concen-
tration of ROS and RNS in the cellular environment, oxidants can initiate and promote the 
oncogenic phenotype or induce apoptosis, and thus act as antitumor agents [32]. Several tran-
scription factors that modulate the expression of genes critical to the development and metas-
tasis of cancer cells are known to be controlled by oxidative stress. This includes hypoxia 
inducible factor (HIF)-1α, nuclear factor (NF)-κB, peroxisome proliferator-activated receptor 
(PPAR)-γ, activator protein (AP)-1, β-catenin/Wnt, and Nuclear factor erythroid 2-related fac-
tor 2 (Nrf2) [13]. The transcription factor regulator Nrf2 is known to control the expression of 
some key antioxidant enzymes that are needed to scavenge oxidants and free radicals [13, 33]. 
The activation of Nrf2 involves the suppressor protein, Kelch-like ECH-associated protein 1 
Figure 1. Summary of key oxidant and antioxidants in cancer [1]. Abbreviations are CAT, catalase; Cl−, chloride ion; Fe
2
+, 
iron (II); Fe
3
+, iron (III); GPX, glutathione peroxidase; GSH, glutathione; GSR, glutathione reductase; GSSG, reduced 
glutathione; GST, glutathione S-transferase; H
2
O
2
, hydrogen peroxide; H
4
B, tetrohydrobiopterin; HO•, hydroxyl radical; 
HOCl, hypochlorous acid; iNOS, inducible nitric oxide synthase; L-Arg, L-arginine; MPO, myeloperoxidase; NAD(P)H, 
nicotinamide adenine dinucleotide phosphate; NO•+, nitrosonium cation; NO
2
−, nitrite; NO
3
−, nitrate; O
2
•−, superoxide; 
ONOO−, peroxynitrite; SOD, superoxide dismutase.
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(Keap1), that binds Nrf2 in the cytoplasm and prevents its translocation into the nucleus, 
where it binds to promoters of antioxidant enzymes [13, 33]. Additionally, oxidative stress is 
known to activate certain signaling pathways, specifically, the MAPK/AP-1 and NF-κB path-
ways, which are critical for the initiation and maintenance of the oncogenic phenotype [34].
More importantly, ROS and RNS are known to induce genetic mutations that alter gene expres-
sion as well as induce DNA damage, and thus have been implicated in the etiology of several 
diseases, including cancer [2, 13, 35]. Damage to DNA by ROS and RNS is now accepted as a 
major cause of cancer, and has been demonstrated in the initiation and progression of several 
cancers including breast, hepatocellular carcinoma, and prostate cancer [34]. Oxidative stress is 
known to modify all the four DNA bases by base pair substitutions rather than base deletions 
and insertions. Modification of GC base pairs usually results in mutations, whereas, modifica-
tion of AT base pairs does not [36]. Modification of guanine in cellular DNA, causing G to T 
transversions, is commonly induced by ROS and RNS [34]. If not repaired, the transversion of G 
to T in the DNA of oncogenes or tumor suppressor genes can lead to initiation and progression 
of cancer. Oxidation of DNA bases, such as thymidine glycol, 5-hydroxymethyl-2′-deoxyuridine, 
and 8-OHdG are now accepted markers of cellular DNA damage by free radicals [35].
Oxidants and free radicals are known to enhance cell migration contributing to the enhance-
ment of tumor invasion and metastasis, main causes of death in cancer patients [2, 13]. Reactive 
oxygen species, through the activation of NF-κB, regulate the expression of intercellular adhe-
sion protein-1 (ICAM-1), a cell surface protein in various cell types [13]. In response to oxida-
tive stress, the interleukin 8 (IL-8)-induced enhanced expression of ICAM-1 on neutrophils 
enhances the migration of neutrophils across the endothelium, which is key in tumor metasta-
sis [13]. Another important player that controls cell migration and consequently, tumor inva-
sion, is the upregulation of specific matrix metalloproteinases (MMPs), essential enzymes in 
the degradation of most components of the basement membrane and extracellular matrix, 
such as type IV collagen [13, 37]. The expression of MMPs, such as MMP-2, MMP-3, MMP-9, 
MMP-10, and MMP-13 is enhanced by free radicals, specifically H
2
O
2
 and NO, through the 
activation of Ras, ERK1/2, p38, and JNK, or the inactivation of phosphatases [13, 37]. Indeed, 
the major source of cellular ROS, the NAD(P)H oxidase family of enzymes, has been linked 
to the promotion of survival and growth of tumor cells in pancreatic and lung cancers [2, 13].
Oxidants and free radicals are also known to enhance angiogenesis, a key process for the survival 
of solid tumors [13]. Angiogenesis involves the upregulation of vascular endothelial growth fac-
tor (VEGF) or the downregulation of thrombospondin-1 (TSP-1), an angiogenesis suppressor in 
response to oxidative stress [13]. This process is controlled by several oncogenes and tumor-sup-
pressor genes such as Ras, c-Myc, c-Jun, mutated p53, human epidermal growth factor receptor-2, 
and steroid receptor coactivators [38, 39]. Additionally, oxidants and free radicals are known to 
stabilize HIF-1α protein and induce the production of angiogenic factors by tumor cells.
4. Cancer cells are under intrinsic oxidative stress
Cancer cells are continuously exposed to high levels of intrinsic oxidative stress due to increased 
aerobic glycolysis (Warburg effect), a known process in cancer cell metabolism [10, 40]. 
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Thus, cancer cells trigger several critical adaptations that are essential for their survival such 
as suppression of apoptosis, alteration of glucose metabolism, and stimulation of angiogen-
esis [10, 29]. Oxygen depletion, due to a hypoxic microenvironment, significantly stimulates 
mitochondria to produce high levels of ROS and RNS which is known to activate HIF-1α 
and consequently promote cell survival in such an environment [29]. The half-life of HIF-1α 
is extremely short as it is rapidly inactivated through hydroxylation reactions mediated by 
dioxygen, oxaloglutarate, and iron-dependent prolyl 4-hydroxylases, located in the nucleus 
and cytoplasm [40, 41]. Nitric oxide and other ROS, as well as H
2
O
2
 efflux into the cytosol due 
to dismutation of O
2
●−, can inhibit prolyl 4-hydroxylases activity, leading to the stabilization 
of HIF-1α [29, 42]. More importantly, stabilization of HIF-1α, under hypoxic conditions, can 
be blocked when inhibiting ROS production in mitochondria that lack cytochrome c [29, 43].
Pro-oxidant enzymes such as myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS) 
and NAD(P)H oxidase have been associated with initiation, progression, survival, and 
increased risk in cancers such as breast, ovarian, lung, prostate, bladder, colorectal and malig-
nant melanoma [21, 44]. Moreover, the expression of those key pro-oxidant enzymes was 
found to change based on the histological type and grade of the tumor [21, 45, 46]. Likewise, 
antioxidants have also been associated with initiation, progression, survival, and increased 
risk in cancers such as lung, head and neck, and prostate cancer [47–50]. The expression of 
GSR and GPX, key antioxidant enzymes, has also been reported to be altered in various types 
of cancer [21]. The activity and expression of SOD, a powerful antioxidant enzyme, has been 
reported to be decreased in colorectal carcinomas, pancreatic, lung, gastric, ovarian, and 
breast cancers [21, 45, 46]. Likewise, the expression and activity of CAT, a key antioxidant 
enzyme, was reported to be decreased in breast, bladder, and lung cancers but increased in 
brain cancer [21, 45, 46]. Antioxidant enzymes play a critical role in maintaining the redox 
balance in the presence of microenvironment stress, and thus, alteration of this balance may 
provide a unique and complex microenvironment for cancer cell survival.
5. Ovarian cancer cells manifest a persistent pro-oxidant state
Recent evidence suggests that oxidative stress is a critical factor in the initiation and develop-
ment of several cancers, including ovarian cancer [40, 51]. Consistently, it has been reported 
that ovarian cancer patients manifested significantly decreased levels of antioxidants and 
higher levels of oxidants [10, 22, 40, 51–53]. An enhanced redox state, resulting from increased 
expression of key pro-oxidant enzymes and decreased expression of antioxidant enzymes, has 
been extensively described in epithelial ovarian cancer (EOC) [52–54]. We have previously 
reported that MPO, a hemoprotein present solely in myloid cells that acts as a powerful oxi-
dant, and iNOS, a key pro-oxidant enzyme, are highly expressed and co-localized to the same 
cell in EOC cells [53]. These two enzymes, MPO and iNOS, work together to inhibit apop-
tosis, a hallmark of ovarian cancer cells. Nitric oxide, produced by iNOS, is used by MPO 
as a one-electron substrate to generate nitrosonium cation (NO+), a labile nitrosating species, 
resulting in a significant increase in S-nitrosylation of caspase-3, which inhibits apoptosis [53, 
55, 56]. Indeed, attenuating oxidative stress by inhibiting MPO or iNOS significantly induced 
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 apoptosis in EOC cells [54]. Moreover, the remarkably higher levels of iNOS/NO, produced 
by EOC cells, resulted in the generation of high levels of nitrate and nitrite, powerful protein 
nitration agents that are known to stimulate the initiation and progression of tumor cells [53]. 
Under oxidative stress, where both NO and O
2
●– are elevated, MPO was reported to serve as 
a source of free iron which reacts with H
2
O
2
 and generated highly reactive hydroxyl radical 
(HO●), further increasing oxidative stress [22, 53]. Additionally, EOC cells are also character-
ized by enhanced expression of NAD(P)H oxidase, a potent oxidant enzyme that is known 
to be the major source of O
2
●– in the cell. Such high levels of O
2
●– combined with significantly 
high levels of NO generates peroxynitrite, another powerful nitrosylation and nitration agent, 
which modifies proteins and DNA structure and function in cells [57].
Recently we have gathered compelling evidence demonstrating that talc, through alteration 
of the redox balance, can generate a similar pro-oxidant state in both normal ovarian epithe-
lial and ovarian cancer cells. Talc and asbestos are both silicate minerals, and the carcinogenic 
effects of asbestos have been extensively studied and documented in the medical literature 
[58]. Asbestos fibers in the lung initiate an inflammatory and scarring process, and it has been 
proposed that ground talc, as a foreign body, might initiate a similar inflammatory response 
[58]. Although there is strong epidemiological evidence to suggest an association between talc 
use and ovarian cancer, the direct link and precise mechanisms have yet to be elucidated. We 
investigated the effect of talc on both oxidants and antioxidants in normal ovarian epithelial 
and ovarian cancer cell lines. There was a marked increase in mRNA levels of the pro-oxidant 
enzymes, iNOS and MPO in talc treated ovarian cancer cell lines and normal ovarian epi-
thelial cells, all as compared to their control, as early as 24 hours. Additionally, there was a 
marked decrease in the mRNA levels of the antioxidant enzymes CAT, GPX, SOD3, but with 
a marked increase in GSR, and no change in GST, in talc treated ovarian cancer cell line and in 
normal ovarian epithelial cells, all compared to their control, as early as 24 hours (data not pub-
lished). Thus, there is a direct effect of talc on the molecular levels of oxidant and antioxidants, 
elucidating a potential mechanism for the development of ovarian cancer in response to talc.
6. Biomarkers for the early detection of ovarian cancer
The discovery of MPO expression in ovarian EOC cells and tissues was surprising, as it is only 
expressed by cells of myeloid origin. Intriguingly, the combination of serum MPO and free 
iron was reported to potentially serve as biomarkers for early detection of ovarian cancer [22]. 
A robust detection method based on molecular profiles for ovarian cancer has not yet been 
developed because the disease exhibits a wide range of morphological, clinical and genetic 
variations during its progression. The search for non-invasive, cost-effective ovarian cancer 
biomarker tests has been ongoing for many years. Immunizations of mice with ovarian cancer 
cells has led to hybridoma validation by ELISA, while flow cytometry analysis permitted the 
discovery of cancer antigen (CA)-125 and mesothelin [59]. Furthermore, the screening of an 
array of 21,500 unknown ovarian cDNAs hybridized with labeled first-strand cDNA from ten 
ovarian tumors and six normal tissues led to the discovery of human epididymis protein 4 
(HE4) [60]. Most interestingly, HE4 is overexpressed in 93% of serous and 100% of endometrioid 
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EOCs, and in 50% of clear cell carcinomas, but not in mucinous ovarian carcinomas [61]. 
Thus, HE4 was identified as one of the most useful biomarkers for ovarian cancer, although it 
lacked tissue-specificity [60, 62–64]. Secreted HE4 high levels were also detected in the serum 
of ovarian cancer patients [65]. Additionally, combining CA-125 and HE4 is a more accurate 
predictor of malignancy than either alone [66–68].
Multi-marker panels have the potential for high positive predictive values (PPVs), but careful 
validation with appropriate sample cohorts is mandatory and complex algorithms may be 
difficult to implement for routine clinical use [59]. Panels of biomarkers have been extensively 
investigated to improve sensitivity and specificity and have included some of the most prom-
ising reported markers such as CA72–4, M-CSF, OVX1, LPA, prostacin, osteopontin, inhibin 
and kallikrein [69–71]. However, most of these tests frequently require certain equipments 
and complex computational algorithms that may not be available in a standard immunoas-
say laboratory, [32]. Among postmenopausal women in the U.S., only 1 in 2500 women are 
reported with ovarian cancer. Due to this low prevalence of the disease, a screening method 
that yield a 75% sensitivity and 99.6% specificity to achieve a PPV value of 10% to be effective 
for the detection of all stages of ovarian cancer [72]. To date, there is no single biomarker avail-
able that met these requirements.
The established role of MPO in oxidative stress and inflammation has been a leading factor 
in the study of MPO as a possible marker of plaque instability and a useful clinical tool in 
the evaluation of patients with coronary heart disease [73]. Recent genetic studies implicated 
MPO in the development of lung cancer by demonstrating a striking correlation between the 
relative risk for development of the disease and the incidence of functionally distinct MPO 
polymorphisms [74]. Myeloperoxidase levels reported for various inflammatory disorders are 
coincidentally lower than those levels found in all stages of ovarian cancer. A previous study 
reported normal serum MPO and iron levels as 62 ± 11 ng/ml and 96 ± 9 μg/dl, respectively 
[75]. However, there was a significant increase in serum MPO and iron levels to 95 ± 20 ng/ml 
and 159 ± 20 μg/dl, respectively, in asthmatic individuals [75]. Although there was an increase 
in this reported serum iron, these levels still fell within the normal range (50 to 170 μg/dl) 
[22, 75]. Other studies have showed that an elevated MPO levels, reaching up to 350 ng/ml, 
in serum plasma, was indicative of a higher risk for cardiovascular events in patients hospi-
talized for chest pain [76, 77]. A recent study showed a significant correlation between MPO 
levels and the stage of ovarian cancer, as is the linear trend for MPO with increasing stage 
[22]. Similarly, there was a significant difference in the level of free iron in serum and tissues 
obtained from stage I as compared to combined stages II, III, and IV ovarian cancer. There 
was an overlap between stage I ovarian cancer and inflammation (endometriosis) serum MPO 
levels, however serum free iron levels were significantly higher in stage I ovarian cancer as 
compared to inflammation. There was no significant change in free iron levels between the 
healthy control group, benign gynecologic conditions group, and inflammation group [22].
Due to the overlap of MPO levels in early-stage ovarian cancer and inflammatory conditions, 
there is a potential for a false positive with MPO alone in patients with cardiovascular, inflam-
mation, and/or asthmatic disorders. It has been reported that MPO heme destruction and iron 
release is mediated by high levels of both HOCl (a product of MPO) and oxidative stress (i.e. can-
cer) [22]. The free iron generated by hemoprotein destruction not only contributes to elevation of 
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serum iron levels, but may also induce oxidative stress, which can promote lipid peroxidation, 
DNA strand breaks, and modification or degradation of biomolecules [78–80]. Iron reacts with 
H
2
O
2
 and catalyzes the generation of highly reactive hydroxyl radicals, which in turn further 
increases free iron concentrations by the Fenton and Haber–Weiss reaction [81]. Several studies 
from our laboratories have provided a mechanistic link between oxidative stress, MPO, higher 
levels of HOCl and higher free iron that could explain the observed accumulation of free iron in 
epithelial ovarian cancers tissues [53, 82–85]. Utilizing serum iron levels alone as a biomarker is 
also not sufficient for early detection of ovarian cancer due to many uncontrolled variables, i.e. 
dietary intake, supplements, effects of other iron-generating enzymes or factors, and more impor-
tantly they are not as specific as MPO levels. Specifically, in iron deficiency anemic patients, their 
free iron levels may become a confounding factor in its utilization for early detection of ovarian 
cancer. Thus, anemia should be ruled out to eliminate any overlap that would lead to misdiagno-
sis. The incorporation of iron deficiency anemic patients in a logistic regression model will help 
determine its overlap with early-stage ovarian cancer. Additionally, currently available clinical 
studies focused on either biochemical or more recently, genetic markers of iron overload have 
reported conflicting results regarding the use of iron levels alone for diagnosis [86–89].
Thus, the combination of serum MPO and iron levels should yield a higher power of speci-
ficity and sensitivity that should distinguish women with early-stage ovarian cancer from 
other disorders, specifically inflammation [22]. Additionally, combining serum MPO and iron 
levels with the best currently existing biomarkers through the creation of a logistic regression 
model may increase the overall predictive values. Collectively, there is a role for serum MPO 
and free iron in the pathophysiology of ovarian cancer, which thereby qualifies them to serve 
as biomarkers for early detection and prognosis of ovarian cancer.
7. Modulation of oxidative stress
Several studies have reported the beneficial effects of modulating the redox status of cancer 
cells, however few studies have been reported for ovarian cancer [90–92]. Inhibition of pro-
oxidant enzymes, such as NAD(P)H oxidase, has been shown to significantly induce apopto-
sis of cancer cells [93, 94]. We investigated whether NAD(P)H oxidase-mediated generation 
of intracellular reactive ROS lead to anti-apoptotic activity and thus a growth advantage to 
EOC cells. Diphenyleneiodonium (DPI) has been used to inhibit ROS production mediated by 
NAD(P)H oxidase in various cell types [95–97]. Our results showed that NAD(P)H oxidase is 
over-expressed in EOC tissues and cells as compared to normal ovarian tissues and cells [52]. 
Indeed, high levels of NAD(P)H oxidase are known to promote tumorigenesis of NIH3T3 
mouse fibroblasts and the DU-145 prostate epithelial cells [98].
Inhibition of NAD(P)H oxidase has also been reported to decrease the generation of O
2
●–, H
2
O
2
, 
as well as other oxidants [93, 94]. Cancer cells are known to manifest enhanced intrinsic oxida-
tive stress and metabolic activity that lead to mitochondrial failure [99, 100]. Indeed, it was 
previously reported that ovarian tumors are characterized by increased ROS levels as evident 
from increased O
2
●– generated from NAD(P)H oxidase as well as mitochondrial malfunction 
[101]. The NAD(P)H oxidase redox signaling is controlled by mitochondria, and thus loss of 
New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress
http://dx.doi.org/10.5772/intechopen.73860
91
this control is thought to contribute to tumorigenesis [101]. Others have also shown that inhi-
bition of NAD(P)H oxidase induced apoptosis in cancer cells [102]. Continuous ROS produc-
tion by the cell and the environment further induces the inhibition of phosphorylation of AKT 
and subsequent suppression of AKT-mediated phosphorylation of ASK1 on Ser-83, resulting 
in significant decrease in apoptosis [102–104]. Furthermore, paclitaxel, a chemotherapeutic 
agent used in the treatment of ovarian cancer and other cancers, induced apoptosis of ovarian 
cancer cells by negative regulation of AKT–ASK1 phosphorylation signaling [102–104]. On 
the other hand, activation of AKT by ROS provided protection against apoptosis [102–104].
Data from our laboratory clearly demonstrated that treatment of EOC cells with DPI, which 
inhibits ROS production mediated by NAD(P)H oxidase, significantly reduced SOD3 and 
HIF-1α mRNA and protein levels as early as 30 minutes after treatment with a concomi-
tant increase in apoptosis [52]. The association between increased HIF-1α expression and 
decreased cellular apoptosis has also been demonstrated in lung and hepatoma cancer cells 
[94, 105]. Overexpression of HIF-1α is thought to decrease apoptosis by the upregulation of 
anti-apoptotic proteins, Bcl-2 and Bcl-xL and down regulation of pro-apoptotic proteins, BAX 
and BAK [106]. Inhibition of HIF-1α by rapamycin increased apoptosis by decreasing the 
expression of apoptosis inhibitor Bcl-2 in ovarian cancer xenografts [107]. Additionally, inhi-
bition of HIF-1α by rapamycin enhanced apoptosis through the inhibition of cell survival 
signals in several other cell lines [107].
Most of the NAD(P)H oxidase-generated O
2
●– is utilized to produce H
2
O
2
 by nonenzymatic 
or SOD-catalyzed reactions [108–110]. Hydrogen peroxide serves as the precursor of more 
toxic hydroxyl radicals and thus is extremely destructive to cells and tissues [109–111]. The 
expression of SOD3 was reported to increase in response to intrinsic oxidative stress in ovar-
ian cancer cells [112]. It has been demonstrated that overexpression of the SOD3 gene signifi-
cantly suppressed lung cancer metastasis as well as inhibited the growth of B16-F1 melanoma 
tumors in mice [113, 114]. However, in a somewhat controversial study, it has been shown 
that inhibition of SOD selectively induced apoptosis of leukemia and ovarian cancer cells [10].
Under hypoxic conditions, SOD3 is overexpressed and has been reported to significantly 
induce the expression of HIF-1α in tumors through unknown mechanisms however, steady 
state levels of O
2
●– and the stabilization of HIF-1α have been proposed to play a role in this 
mechanism [107, 115]. Therefore, inhibition of NAD(P)H oxidase and the consequent reduc-
tion of O
2
●– levels may destabilize HIF-1α, and subsequently increase apoptosis by lowering 
SOD3 levels. Thus, we conclude that lowering oxidative stress, possibly through the inhibi-
tion of NAD(P)H oxidase-generated O
2
●–, induces apoptosis in ovarian cancer cells and may 
serve as a potential target for cancer therapy. This effect was attributed to the modulation of 
key enzymes that are central to controlling the cellular redox balance.
8. Modulation of metabolism
Cancer cells are known to favor anaerobic metabolism, even when oxygen is present and is 
known as the “Warburg effect” [116, 117]. Aerobic glycolysis is known to decrease ATP yield as 
well as increase lactate production by cancer cells [116–118]. To compensate for this decrease in 
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ATP, cancer cells significantly increase glucose uptake through upregulation of glucose recep-
tors [40, 41, 118]. Increased lactate in cancer cells enhances lactic acidosis, which is significantly 
toxic to the surrounding tissues and can facilitate tumor growth through the stimulation of 
ECM degradation, angiogenesis, and metastasis [118]. Additionally, aerobic glycolysis in can-
cer cells activates HIF, an oxygen-sensitive transcription factor that plays an important role 
in initiation and maintenance of the oncogenic phenotype [118]. In this regard, HIF induces 
the expression of several glucose transporters and glycolysis enzymes as well as induces the 
expression of pyruvate dehydrogenate kinase (PDK), an enzyme that stimulates pyruvate entry 
into the mitochondria for oxidation [41, 118, 119]. Thus, shifting glucose metabolism in cancer 
cells from glycolysis to glucose oxidation may have therapeutic value [120]. Indeed, inhibiting 
PDK by dichloroacetate (DCA) has been reported to induce apoptosis in tumor cells and sig-
nificantly decreased HIF-1α expression [40]. More importantly DCA is currently in the clinical 
use for the treatment of hereditary mitochondrial diseases as well as lactic acidosis [41, 121]. 
The use of DCA at a dose of 35 to 50 mg/kg decreased lactate levels by more than 60% [41, 122]. 
Dichloroacetate treatment has been shown to significantly induce apoptosis, through the stim-
ulation of caspase-3 activity, in a dose-dependent manner in EOC cells as well as other cancers, 
such as glioblastoma, endometrial, prostate, and non-small cell lung cancers [40, 123]. Aerobic 
glycolysis is associated with resistance to apoptosis in cancer cells as many of the enzymes in 
the glycolysis process are known to modulate gene transcription of apoptotic proteins [40, 41, 
69, 124]. Stimulation of pyruvate entry into the mitochondria by DCA, through activation of 
PDH and inhibition of PDK, is an ideal method to shift aerobic glycolysis to glucose oxidation 
as inhibiting aerobic glycolysis results in ATP depletion and necrosis, not apoptosis [41, 125].
An additional approach to induce apoptosis in cancer cells is through scavenging high levels 
of oxidants produced by cancer cells utilizing antioxidants [126]. Deficiency in SOD or inhibi-
tion of SOD enzyme activity causes accumulation of O
2
•− which is the precursor for several 
toxic free radicals that are critical to the oncogenic process [127]. Elevated levels of oxidants 
and free radicals are also known to induce cellular senescence and necrosis, and thus can kill 
tumor cells [40, 128]. The precise effect of high levels of oxidants and free radicals in cancer 
cells will depend on the type of cells and tissues, the site of production, and the type and 
concentration of oxidants [13].
9. Chemotherapy and the acquisition of chemoresistance in EOC cells
Resistance to taxanes and platinums, chemotherapy drugs in current use for ovarian cancer 
treatment, remains a major obstacle to a successful treatment of ovarian cancer patients [6]. 
Resistance to chemotherapy not only limits the use of the initial drug but also limits the use of 
other agents, even those with different mechanisms of action [129]. Chemotherapy drugs exert 
their actions by the initiation of cell death either directly through the generation of oxidative 
stress or as an indirect effect of exposure, as observed with several chemotherapeutic agents 
[130]. The development of chemoresistance to drugs is dependent on several factors that include: 
influx/efflux of drugs that decrease platinum accumulation in tumor cells, enhanced GSH and 
GST levels, upregulation of anti-apoptotic proteins such as Bcl-2, loss of tumor necrosis factor 
receptor ligand which induces apoptosis, increased DNA repair through up-regulation of repair 
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genes, and loss of functional p53 that augments NF-κB activation [13, 131]. We have previously 
shown that chemoresistant EOC cells manifested increased iNOS and nitrate/nitrite levels as 
well as a decrease in GSR expression as compared to sensitive EOC cells, suggesting a further 
enhancement of the redox state in chemoresistant cells [1, 45]. Additionally, CAT, GPX, and 
iNOS were shown to be significantly increased while, GSR, SOD, and the NAD(P)H oxidase 
subunit (p22phox) were decreased in chemoresistant EOC cells as compared to their sensitive 
counterparts [21]. These finding supports a key role for oxidative stress, not only in the develop-
ment of the oncogenic phenotype, but also in the development of chemoresistance (Figure 2).
10. Common polymorphisms in redox enzymes are associated with 
ovarian cancer
A single nucleotide polymorphism (SNP) occurs as a result of gene point mutations with 
an estimated frequency of at least one in every 1000 base pairs that are selectively main-
tained and distributed in populations throughout the human genome [132]. An association 
Figure 2. Summary of the role of oxidative stress in the development of sensitive and chemoresistant ovarian cancer [1].
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between common SNPs in oxidative DNA repair genes and redox genes with human cancer 
susceptibility has been established [28]. Common SNPs in the redox enzymes are known to be 
strongly associated with an altered enzymatic activity in these enzymes, and may explain the 
enhanced redox state that has been linked to several malignancies, including ovarian cancer 
[40, 52]. Additionally, it may further explain the observation of significantly decreased apop-
tosis and increased survival of EOC cells [53]. It is therefore critical to determine the exact 
effect of common SNPs in various redox enzymes on all process involved in the development 
of the oncogenic phenotype [21, 46, 133, 134]. Such studies can be linked to other studies 
focusing on determining the effects of genes involved in carcinogen metabolism (detoxifica-
tion and/or activation), redox enzymes, and DNA repair pathways [133]. Numerous SNPs 
associated with change of function have been identified in antioxidant enzymes including 
CAT, GPX1, GSR, and SOD2 [21, 134]. Additionally, the association between genetic poly-
morphisms in genes with anti-tumor activity and those involved in the cell cycle has been 
reported in ovarian cancer [135, 136]. Recently, several genetic variations have been identi-
fied in genome-wide association studies (GWAS), and were found to act as low to moderate 
penetrant alleles, which contribute to ovarian cancer risk, as well as other diseases [23, 137].
There is now an association of specific SNPs in key oxidant and anti-oxidant enzymes with 
increased risk and overall survival of ovarian cancer [21, 46]. A common SNP that reduced 
CAT activity (rs1001179) was utilized as a significant predictor of death when present in ovar-
ian cancer patients and was also associated with increased risk for breast cancer [21, 46, 134, 
138]. This SNP is also linked to increased risk, survival, and response to adjuvant treatment of 
cancer patients, including ovarian [46, 139]. Another common SNP that reduced CYBA activ-
ity (rs4673) was also reported to be associated with an increased risk for ovarian cancer [21, 
46]. The mutant genotype of the CYBA gene has been shown to both decrease and increase 
activity of the protein, thereby altering the generation of O
2
●– [21, 46]. Moreover, function-
ally distinct MPO polymorphisms, such as (rs2333227) have been linked to relative increased 
risk for development of ovarian cancer as well as other cancers [21, 44, 46]. Additional SNPs 
that influenced the risk of EOC have been successfully identified from the GWAS studies 
including rs3814113 (located at 9p22, near BNC2), rs2072590 (located at 2q31, which contains 
a family of HOX genes), rs2665390 (located at 3q25, intronic to TIPARP), rs10088218 (located 
at 8q24, 700 kb downstream of MYC), rs8170 (located at 19p13, near MERIT40), and rs9303542 
(located at 17q21, intronic to SKAP1) [21, 46]. Thus, the genetic component of increased ovar-
ian cancer risk may be attributed to SNPs that result in point mutations in the redox genes and 
potentially other genes [140].
11. Chemoresistance is associated with point mutations in key redox 
enzymes in EOC cells
To date, the acquisition of chemoresistance in ovarian cancer is not fully understood. The 
enhanced oxidant state reported in chemoresistant EOC cells may be linked to point mutations in 
key redox enzymes [21]. Chemoresistant EOC cells manifested increased levels of CAT, GPX, and 
iNOS and decreased levels of GSR, SOD, and NAD(P)H oxidase as compared to their sensitive 
counterparts [21]. Interestingly, chemoresistant EOC cells, and not their sensitive counterparts, 
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manifested specific point mutations that corresponded to known functional SNPs, in key redox 
enzymes including SOD2 (rs4880), NOS2 (rs2297518), and CYBA (rs4673) [1]. However, altered 
enzymatic activity for CAT and GSR observed in chemoresistant EOC cells did not correspond 
to the specific SNP of interest in those enzymes, indicating involvement of other possible func-
tional SNPs for those enzymes [21]. Coincidently, chemotherapy treatment induced point 
mutations that happen to correspond to known functional SNPs in key oxidant enzymes subse-
quently led to the acquisition of chemoresistance by EOC cells. Indeed, the induction of specific 
point mutations in SOD2 or GPX1 in sensitive EOC cells resulted in a decrease in the sensitivity 
to chemotherapy of these cells [21]. In fact, the addition of SOD to sensitive EOC cells during 
chemotherapy treatment synergistically increased the efficacy to chemotherapy [21].
Alternatively, the observed nucleotide switch in response to chemotherapy in EOC cells may 
be the result of nucleotide substitution, a process that includes transitions, replacement of 
one purine by the other or that of one pyrimidine by the other, or transversions, replacement 
of a purine by a pyrimidine or vice versa [21]. Indeed, hydroxyl radicals are known to react 
with DNA causing the formation of many pyrimidine and purine-derived lesions [21]. The 
oxidative damage to 8-Oxo-2′-deoxyguanosine, a major product of DNA oxidation, induces 
genetic alterations in oncogenes and tumor suppressor genes has been involved in tumor ini-
tiation and progression [21]. A GC to TA transversion has been reported in the ras oncogene 
and the p53 tumor suppressor gene in several cancers. However, the GC to TA transversion is 
not unique to hydroxy-2′-deoxyguanosine, as CC to TT substitutions have been identified as 
signature mutations for oxidants and free radicals [21].
Moreover, the observed nucleotide switch in response to chemotherapy in EOC cells can be 
due to the fact that acquisition of chemoresistance generates an entirely different popula-
tion of cells with a distinct genotype. Hence, chemotherapy kills the bulk of the tumor cells 
leaving a subtype of cancer cells with ability for repair and renewal, known as cancer stem 
cells (CSCs) [21]. Indeed, cancer stem cells have been isolated from various types of cancer 
including leukemia, breast, brain, pancreatic, prostate, ovarian and colon [21]. Interestingly, 
CSC populations were present in cultures of SKOV-3 EOC cells and have been shown to be 
chemoresistance in nature [21].
12. Further increasing pro-oxidant enzymes: potential survival 
mechanism
Apoptosis is a tightly regulated molecular process that removes excess or unwanted cells from 
organisms. Resistance to apoptosis is a key feature of cancer cells and is involved in the patho-
genesis of cancer. We have previously reported that EOC cells have significantly increased lev-
els of NO, which correlated with increased expression in iNOS [54]. We have also reported that 
EOC cells manifested lower apoptosis, which was markedly induced by inhibiting iNOS by 
L-NAME, indicating a strong link between apoptosis and NO/iNOS pathways in these cells 
[54]. Caspase-3 is known to play a critical role in controlling apoptosis, by participating in a cas-
cade that is triggered in response to proapoptotic signals and culminates in cleavage of a set of 
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proteins, resulting in disassembly of the cell [141–144]. Caspase-3 was found to be S-nitrosylated 
on the catalytic-site cysteine in unstimulated human lymphocyte cell lines and denitrosylated 
upon activation of the Fas apoptotic pathway [145]. Decreased caspase-3 S-nitrosylation was 
associated with an increase in intracellular caspase activity. Caspase-3 S-nitrosylation/deni-
trosylation is known to serve as an on/off switch regulating caspase activity during apopto-
sis in endothelial cells, lymphocytes and trophoblasts [146–149]. The mechanisms underlying 
S-nitrosothiol (SNO) formation in vivo are not well understood.
Myeloperoxidase typically uses H
2
O
2
, in combination with chloride to generate hypochlorous 
acid [55, 150–153]. We, and others, have demonstrated that MPO utilizes NO, produced by 
iNOS, as a one-electron substrate generating NO+, a labile nitrosating species that is rapidly 
hydrolyzed forming nitrite as end-product [55, 56, 154, 155]. The ability of MPO to generate 
NO+, from NO, led us to believe that not only does MPO play a role in S-nitrosylation of cas-
pase-3 in EOC cells, but also highlights a possible cross-talk between iNOS and MPO. Indeed, 
we observed that MPO is responsible for the S-nitrosylation of caspase-3, which led to the 
inhibition of caspase-3 in EOC cells. Silencing MPO gene expression induced apoptosis in 
EOC cells through a mechanism that involved S-nitrosylation of caspase-3 by MPO.
Molecular alterations that lead to apoptosis can be inhibited by S-nitrosylation of apoptotic 
proteins such as caspases. Thus, S-nitrosylation conveys a key influence of NO on apoptosis 
signaling and may act as a key regulator for apoptosis in cancer cells. It has been known that 
the effects of NO on apoptosis are not only stimulatory but may also be inhibitory. These para-
doxical effects of NO on apoptosis seem to be influenced by several factors. It has been sug-
gested that biological conditions, such as the redox state, concentration, exposure time and the 
combination with O
2
, O
2
●– and other molecules, determines the net effect of NO on apoptosis 
[156]. Also, NO is implicated in both apoptotic and necrotic cell death depending on the NO 
chemistry and the cellular biological redox state [57, 156]. As described earlier, we have previ-
ously demonstrated that the EOC cell lines, SKOV-3 and MDAH-2774, manifested lower apop-
tosis and had significantly higher levels of NO due to the presence of elevated levels of iNOS 
[54, 157]. We have also reported significant levels of MPO expression, which was found to be 
co-localized with iNOS, in both EOC cell lines SKOV-3 and MDAH-2774 [53]. We have dem-
onstrated that 65% of the invasive epithelial ovarian carcinoma specimens tested expressed 
MPO in the neoplastic cells. The co-localization of MPO and iNOS has been demonstrated by 
immunohistochemical studies in cytokine-treated human neutrophils and primary granules 
of activated leukocytes [158]. Both plasma levels and tissue expression of MPO in gynecologic 
malignancies were previously evaluated and it was found that gynecologic cancer patients had 
higher plasma MPO compared to control subjects [159]. Using immunostaining, it was also 
demonstrated that MPO expression was higher in cancer tissues compared to control [159].
We have now characterized chemoresistant EOC cells to manifest an even further increase 
in pro-oxidant enzymes including MPO, and NO, a surrogate for iNOS activity in conjunc-
tion with a further increase in the S-nitrosylation of caspase-3 (data not published) and a con-
current decrease in the level of apoptosis [21]. Thus, we hypothesized that the decrease in 
apoptosis observed in chemoresistant EOC cells is a consequence of a further increase in the 
degree of S-nitrosylation of caspase-3. Since resistance to apoptosis is a hallmark of tumor 
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growth, identifying mechanisms of this resistance such as S-nitrosylation may be a key in 
cancer progression and the development of chemoresistance. S-nitrosylation is reversible and 
seemingly a specific post-translational modification that regulates the activity of several sig-
naling proteins. S-nitrosylation of the catalytic site cysteine in caspases serves as an on/off 
switch regulating caspase activity during apoptosis in endothelial cells, lymphocytes, and 
trophoblasts [147–149]. Targeting MPO may be a potential therapeutic intervention to reverse 
the resistance to apoptosis in sensitive and chemoresistant EOC cells.
13. Ovarian cancer immunotherapy and oxidative stress
It is well established that tumorigenic cells generate high levels of ROS to activate proximal 
signaling pathways that promote proliferation, survival and metabolic adaptation while also 
maintaining a high level of antioxidant activity to prevent buildup of ROS to levels that could 
induce cell death [160]. Moreover, there is evidence that ROS can act as secondary messengers 
in immune cells, which can lead to hyperactivation of inflammatory responses resulting in tis-
sue damage and pathology [160]. Ovarian cancer is considered an ideal tumorogenic cancer 
because ovarian cancer cells have no negative impact on immune cells [161].
Effective immunotherapy for ovarian cancer is currently the focus of several investigations and 
clinical trials. Current immunotherapies for cancer treatment include therapeutic vaccines, 
cytokines, immune modulators, immune checkpoint inhibitors, and adoptive T cell transfer 
[162]. The discovery of a monoclonal antibodies (such as bevacizumab) directed against VEGF 
have been shown to improve progression free survival compared to cytotoxic chemotherapy 
alone was a major outcome of these clinical trials [163]. Other monoclonal antibodies cur-
rently approved for other cancers such as trastuzumab for breast cancer or cetuximab for 
colon cancer exhibited limited activity in ovarian cancer [163]. Several clinical trials are ongo-
ing for the utilization of immune checkpoint blockade in ovarian cancer immune therapy 
[164]. Most recently tested were the programmed death (PD)-1 inhibitors, pembrolizumab 
and nivolumab, which showed a consistent response rate of 10–20% in phase 2 studies and 
then failed to improve outcomes in confirmatory trials [164]. Ultimately, larger phase 3 stud-
ies are needed to validate these findings for checkpoint inhibitors, particularly with regard 
to the duration of response seen with these agents. Additionally, the direct intraperitoneal 
delivery of interleukin (IL)-12, a potent immunostimulatory agent, exhibited some potential 
therapeutic efficacy in ovarian cancer [165]. Recently, targeting folate receptor alpha, which 
is found to be expressed in ovarian cancer, has shown promising therapeutic value. The tar-
geting of the folate receptor was achieved by either a blocking monoclonal antibody (farletu-
zumab) or antibody conjugates of folate analogs, such as vintafolide [166].
14. Summary and conclusion
Oxidative stress has been implicated in the pathogenesis of several malignancies including 
ovarian cancer. Epithelial ovarian cancer is characterized to manifest a persistent pro-oxidant 
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state through alteration of the redox balance, which is further enhanced in their chemoresis-
tant counterparts, as summarized in Figure 2. Forcing ovarian cancer cells to undergo oxida-
tive phosphorylation rather than glycolysis has been shown to be beneficial for eliminating 
cells via apoptosis (Figure 2). Collectively, there is convincing evidence that indicated a causal 
relationship between the acquisition of chemoresistance and chemotherapy-induced genetic 
mutations in key redox enzymes, leading to a further enhanced oxidative stress in chemo-
resistant EOC cells. This concept was further confirmed by the observation that induction 
of point mutations in sensitive EOC cells increased their resistance to chemotherapy. Also, 
a combination of antioxidants with chemotherapy significantly sensitized cells to chemo-
therapy. Identification of targets for chemoresistance with either biomarker and/or screening 
potential will have a significant impact for the treatment of this disease.
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